Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06399757
Title field or adapter rule
{'original_value': 'A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:24.167008+00:00
Published At
2026-10-05T00:00:00+00:00
Record Updated At
2026-10-05
Source Retrieved At
2026-10-31T22:17:54.613222+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Colorectal Cancer", "Cholangiocarcinoma", "Appendiceal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Gastric Adenocarcinoma", "Endometrial Adenocarcinoma", "Triple Negative Breast Cancer", "Ovarian Cancer", "Prostate Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-05", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT06399757"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
  • Appendiceal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Gastric Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Prostate Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Phase 1: Dose Escalation'], 'description': 'APL-5125 is an oral drug (capsule) taken daily in 28-day cycles', 'name': 'APL-5125', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • APL-5125 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.